NOVEL INDOLE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES
申请人:Merck Patent GmbH
公开号:US20160168090A1
公开(公告)日:2016-06-16
The present invention relates to indole compounds, and pharmaceutically acceptable compositions thereof, useful as antagonists of P2X7, and for the treatment of P2X7-related disorders.
本发明涉及吲哚化合物及其药用可接受的组合物,用作P2X7拮抗剂,用于治疗与P2X7相关的疾病。
[EN] BENZAMIDE INHIBITORS OF THE P2X7 RECEPTOR<br/>[FR] INHIBITEURS BENZAMIDIQUES DU RECEPTEUR P2X7
申请人:PFIZER PROD INC
公开号:WO2004099146A1
公开(公告)日:2004-11-18
The present invention provides benzamide inhibitors of the P2X7 receptor of the formula (I), wherein R1 -R3 are as defined herein. The compounds of the invention are useful in the treatment of IL-1 mediated disorders, including, without limitation, inflammatory diseases such as osteoarthritis and rheumatoid arthritis; allergies, asthma, COPD, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.
[EN] INDOLIZINE DERIVATIVES WHICH ARE APPLICABLE TO NEURODEGENERATIVE DISEASES<br/>[FR] DÉRIVÉS D'INDOLIZINE POUVANT ÊTRE EMPLOYÉS DANS DES MALADIES NEURODÉGÉNÉRATIVES
申请人:MERCK PATENT GMBH
公开号:WO2016019228A1
公开(公告)日:2016-02-04
The present invention relates to indolizine compounds, and pharmaceutically acceptable compositions thereof, useful as antagonists of P2X7, and for the treatment of P2X7-related disorders.
本发明涉及吲哚啉化合物及其药学上可接受的组合物,用作P2X7拮抗剂,用于治疗与P2X7相关的疾病。
BENZAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS
申请人:Hilpert Kurt
公开号:US20140073651A1
公开(公告)日:2014-03-13
The invention relates to benzamide derivatives of formula (I),
wherein R
1
, R
2
, R
3
, R
4
, R
5
, R
6
, n and Y are as defined in the description, their preparation and their use as pharmaceutically active compounds.
[EN] BENZAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS DE BENZAMIDE EN TANT QU'ANTAGONISTES DU RÉCEPTEUR P2X7
申请人:ACTELION PHARMACEUTICALS LTD
公开号:WO2012114268A1
公开(公告)日:2012-08-30
The invention relates to benzamide derivatives of formula (I),wherein R1, R2, R3, R4, R5, R6, n and Y are as defined in the description, their preparation and their use as pharmaceutically active compounds.